Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents? (Q30239856)

12 June 2017

title

Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents? (English)

1 reference

12 June 2017

0 references

4

Helena Marzo-Ortega

0 references

Raj Sengupta

object named as

Raj Sengupta

5

0 references

author name string

Andrew Keat

1

1 reference

12 June 2017

Alexander N Bennett

2

1 reference

12 June 2017

Karl Gaffney

3

1 reference

12 June 2017

Tamara Everiss

6

1 reference

12 June 2017

publication date

29 December 2016

1 reference

Rheumatology International

12 June 2017

published in

1 reference

ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Expanding the spectrum of inflammatory spinal disease: AS it was, as it is now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Time to diagnosis of axial spondylarthritis in clinical practice: signs of improving awareness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Fibromyalgia in women with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Undifferentiated spondyloarthritis: a longterm followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

The natural course of radiographic progression in ankylosing spondylitis--evidence for major individual variations in a large proportion of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Thoughts and perceptions of ankylosing spondylitis patients with regard to TNF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

ASAS/EULAR recommendations for the management of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Identifying axial spondyloarthritis in Dutch primary care patients, ages 20-45 years, with chronic low back pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Global prevalence of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Français d'Etude Génétique des Spondylarthropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Socioeconomic burden of immune-mediated inflammatory diseases--focusing on work productivity and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Mortality among patients with ankylosing spondylitis not given X-ray therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Economic considerations of the treatment of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Impact of ankylosing spondylitis on work in patients across the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Sulfasalazine for ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

'It's magic stuff': the experiences of patients with ankylosing spondylitis taking anti-TNF-alpha medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: A multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-016-3635-8

Healthcare costs and productivity losses directly attributable to ankylosing spondylitis

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

The burden of ankylosing spondylitis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

Survival among patients with ankylosing spondylitis: a life-table analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

Undifferentiated spondyloarthropathies: a 2-year follow-up study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

Services for people with ankylosing spondylitis in the UK--a survey of rheumatologists and patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

1 reference

https://pubmed.ncbi.nlm.nih.gov/28035438

12 December 2020

10.1007/S00296-016-3635-8

Identifiers

DOI

1 reference

Dimensions Publication ID

12 June 2017

1020738133

0 references

1 reference